Intech Investment Management LLC cut its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 62.5% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,939 shares of the life sciences company's stock after selling 4,906 shares during the quarter. Intech Investment Management LLC's holdings in Illumina were worth $393,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also recently bought and sold shares of ILMN. WCM Investment Management LLC raised its position in shares of Illumina by 26.6% in the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock worth $551,625,000 after buying an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp increased its stake in Illumina by 0.8% in the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company's stock worth $454,617,000 after acquiring an additional 27,618 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company's stock valued at $354,933,000 after acquiring an additional 48,018 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock valued at $282,735,000 after acquiring an additional 625,245 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Illumina by 4.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company's stock worth $164,334,000 after purchasing an additional 54,319 shares in the last quarter. 89.42% of the stock is owned by institutional investors.
Illumina Stock Down 2.8 %
ILMN traded down $2.28 on Friday, hitting $80.00. The company had a trading volume of 1,526,373 shares, compared to its average volume of 2,212,008. Illumina, Inc. has a 52-week low of $79.30 and a 52-week high of $156.66. The stock has a fifty day simple moving average of $102.80 and a 200-day simple moving average of $126.81. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. The firm has a market capitalization of $12.67 billion, a P/E ratio of -10.42, a P/E/G ratio of 1.60 and a beta of 1.17.
Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Several equities research analysts have issued reports on the stock. Royal Bank of Canada dropped their target price on shares of Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a research report on Wednesday, March 12th. Canaccord Genuity Group dropped their price objective on shares of Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a report on Tuesday, March 11th. Citigroup reduced their target price on Illumina from $130.00 to $90.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Stephens reaffirmed an "overweight" rating and set a $156.00 price target on shares of Illumina in a research note on Tuesday, March 11th. Finally, HSBC cut Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective for the company. in a report on Friday, February 28th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $140.90.
Read Our Latest Report on Illumina
About Illumina
(
Free Report)
Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.
Further Reading
Before you consider Illumina, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Illumina wasn't on the list.
While Illumina currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
